## Clinical Assessment This patient has **inadequately controlled type 2 diabetes** despite monotherapy with metformin: - **HbA₁c 8.9%** (target typically < 7% in most adults) - **Fasting glucose 185 mg/dL** (target 100–130 mg/dL) - **Preserved renal function** (eGFR 78 mL/min/1.73 m²) - **Early diabetic kidney disease** (1+ proteinuria suggests incipient nephropathy) - **Hypertension** (138/88 mmHg) — common comorbidity **Key Point:** This patient requires **intensification of glycemic control** with a second agent. The choice of agent should consider renal protection, cardiovascular benefit, and absence of hypoglycemia risk. ## Type 2 Diabetes Treatment Algorithm (2023 Guidelines) ```mermaid flowchart TD A["Type 2 DM on Metformin<br/>HbA₁c > 7%"]:::outcome --> B{"Comorbidities?"}:::decision B -->|"CKD or Albuminuria"| C["Add SGLT-2i or GLP-1 RA"]:::action B -->|"HF or CVD"| D["Add SGLT-2i or GLP-1 RA"]:::action B -->|"Obesity"| E["Add GLP-1 RA"]:::action B -->|"None / Glycemic only"| F["Add DPP-4i, TZD, or SU"]:::action C --> G["SGLT-2i: renal/CV benefit<br/>GLP-1 RA: CV/weight loss"]:::action D --> H["SGLT-2i preferred if HF<br/>GLP-1 RA if CVD"]:::action E --> I["GLP-1 RA: weight loss<br/>+ CV benefit"]:::action ``` ## Why GLP-1 RA or SGLT-2i? ### SGLT-2 Inhibitors (e.g., empagliflozin, dapagliflozin) - **Renal protection:** Reduce albuminuria and slow CKD progression (EMPA-KIDNEY, DAPA-CKD trials) - **Blood pressure reduction:** 2–4 mmHg systolic - **Cardiovascular benefit:** Reduce heart failure hospitalizations - **Mechanism:** Block glucose reabsorption in proximal tubule → glycosuria + osmotic diuresis ### GLP-1 Receptor Agonists (e.g., dulaglutide, semaglutide) - **Weight loss:** 2–5 kg (important in overweight patients) - **Cardiovascular protection:** Reduce MI/stroke/CV death - **Blood pressure reduction:** 2–3 mmHg systolic - **Mechanism:** Enhance insulin secretion, slow gastric emptying, increase satiety **High-Yield:** Both classes have **proven cardiovascular and renal benefits** beyond glucose lowering. In this patient with **early CKD (proteinuria) and hypertension**, either is appropriate; SGLT-2i may have a slight edge for renal protection. ## Why Each Distractor Is Wrong | Option | Reason | |--------|--------| | **Add amlodipine + recheck HbA₁c in 3 months** | Blood pressure control is important but does NOT address inadequate glycemic control (HbA₁c 8.9%). A second glucose-lowering agent is needed now, not in 3 months. Amlodipine alone is insufficient. | | **Switch metformin to insulin** | Insulin is reserved for advanced type 2 DM or when oral agents fail. Metformin is effective and should be continued; a second agent is added, not a switch. Premature insulin use increases hypoglycemia and weight gain risk. | | **Add sulfonylurea + refer to endocrinology** | Sulfonylureas (e.g., gliclazide) carry high hypoglycemia risk and weight gain. They lack cardiovascular/renal benefits. Endocrinology referral is premature; this is primary-care-level intensification. | ## Treatment Intensification Sequence **Mnemonic:** **GLP-SGLT** = GLP-1 RA and SGLT-2i are **first-line add-ons** to metformin in modern type 2 DM management (ADA 2023, EASD 2023). 1. **Metformin** (first-line, all patients if tolerated) 2. **Add GLP-1 RA or SGLT-2i** (second-line, especially with CKD/CVD/obesity) 3. **Add third agent** (DPP-4i, TZD, or insulin) if HbA₁c still > 7% 4. **Insulin** (last resort, or if eGFR < 30 or severe hyperglycemia) ## Monitoring Plan **Key Point:** After adding GLP-1 RA or SGLT-2i: - Recheck HbA₁c in **8–12 weeks** - Monitor renal function and proteinuria at **6–12 months** - Assess for adverse effects (GLP-1: GI symptoms; SGLT-2i: genital infections, euglycemic DKA) - Continue metformin (synergistic effect) **Clinical Pearl:** SGLT-2i are particularly beneficial in this patient because he has **early diabetic kidney disease** (proteinuria); they slow albuminuria progression and reduce CKD risk.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.